Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study

被引：10

作者：

Pipe, Steven W. ^{[1
]}

Collins, Peter ^{[2
]}

Dhalluin, Christophe ^{[3
]}

Kenet, Gili ^{[4
,5
]}

Schmitt, Christophe ^{[3
]}

Buri, Muriel ^{[3
]}

Jimenez-Yuste, Victor ^{[6
]}

Peyvandi, Flora ^{[7
,8
,9
]}

Young, Guy ^{[10
]}

Oldenburg, Johannes ^{[11
]}

Mancuso, Maria Elisa ^{[12
]}

Kiialainen, Anna ^{[3
]}

Chang, Tiffany ^{[13
]}

Lehle, Michaela ^{[3
]}

Fijnvandraat, Karin ^{[14
]}

机构：

[1] Univ Michigan, Ann Arbor, MI 48109 USA

[2] Cardiff Univ, Sch Med, Cardiff, Wales

[3] F Hoffmann La Roche Ltd, Basel, Switzerland

[4] Sheba Med Ctr, Ramat Gan, Israel

[5] Tel Aviv Univ, Tel Aviv, Israel

[6] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain

[7] Fdn IRCCS CaGranda Osped Maggiore Policlin, Angelo Bianchi Bon Hemophilia, Milan, Italy

[8] Thrombosis Ctr, Milan, Italy

[9] Univ Milan, Milan, Italy

[10] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA

[11] Univ Bonn, Bonn, Germany

[12] IRCCS Humanitas Res Hosp, Rozzano, Italy

[13] Spark Therapeut Inc, San Francisco, CA USA

[14] Univ Amsterdam, Amsterdam, Netherlands

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-157264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 50 条

[1] Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study
Pipe, Steven
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kavakli, Kaan
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Niggli, Markus
Fijnvandraat, Karin
[J]. BLOOD, 2023, 142
[2] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
Pipe, S. W.
Collins, P.
Dhalluin, C.
Kenet, G.
Schmitt, C.
Buri, M.
Jimenez-Yuste, V.
Peyvandi, F.
Young, G.
Oldenburg, J.
Mancuso, M. E.
Kavakli, K.
Kiialainen, A.
Niggli, M.
Chang, T.
Lehle, M.
Fijnvandraat, K.
[J]. HAEMOPHILIA, 2024, 30 : 24 - 25
[3] EMICIZUMAB FOR THE TREATMENT OF INFANTS WITH SEVERE HEMOPHILIA A: INTERIM ANALYSIS OF HAVEN 7
Pipe, Steven
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
ElisaMancuso, Maria
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
[J]. PEDIATRIC BLOOD & CANCER, 2023, 70 : S7 - S7
[4] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH MILD OR MODERATE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: RESULTS FROM THE INTERIM ANALYSIS OF THE HAVEN 6 STUDY
Negrier, C.
Mahlangu, J.
Lehle, M.
Chowdary, P.
Catalani, O.
Jimenez-Yuste, V.
Beckermann, B. M.
Schmitt, C.
Hermans, C.
Ventriglia, G.
Windyga, J.
Kiialainen, A.
d'Oiron, R.
Moorehead, P.
Teodoro, V.
Shapiro, A.
Oldenburg, J.
[J]. HAEMOPHILIA, 2022, 28 : 20 - 21
[5] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
Escobar, Miguel
Agrawal, Neha
Chatterjee, Sagnik
Bhattacharya, Swastik
Caicedo, Jorge
Bullano, Michael
Schultz, Robert G.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
[6] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
Escobar, Miguel
Agrawal, Neha
Chatterjee, Sagnik
Bhattacharya, Swastik
Caicedo, Jorge
Bullano, Michael
Schultz, Bob G. G.
[J]. JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
[7] Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
Callaghan, Michael
Trzaskoma, Benjamin
Ko, Richard H.
Lee, Lucy
Patel, Anisha M.
Tzeng, Eunice
Shah, Michelle Lynn
Chang, Tiffany Y.
Niggli, Markus
Dhalluin, Christophe
Mahlangu, Johnny
[J]. BLOOD, 2019, 134
[8] Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A
Shima, Midori
[J]. JOURNAL OF PEDIATRICS, 2017, 190 : 289 - 289
[9] Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study
Schmitt, Christophe
Adamkewicz, Joanne I.
Xu, Jin
Petry, Claire
Catalani, Olivier
Young, Guy
Negrier, Claude
Callaghan, Michael U.
Levy, Gallia G.
[J]. THROMBOSIS AND HAEMOSTASIS, 2021, 121 (03) : 351 - 360
[10] Factor VIII Use in the Treatment of Breakthrough Bleeds in People with Moderate or Mild Hemophilia A without Factor VIII Inhibitors Receiving Emicizumab Prophylaxis: The Phase III HAVEN 6 Experience
Jimenez-Yuste, Victor
Lim, Elise
Mistry, Ketna
Ventriglia, Giuliana
Shapiro, Amy D.
[J]. BLOOD, 2023, 142

← 1 2 3 4 5 →